Ferozsons Laboratories (KAR:FEROZ) EBIT: ₨2,426 Mil (TTM As of Mar. 2026)


KAR:FEROZ Ferozsons Laboratories Ltd KAR:FEROZ
76 GF Score
Price ₨411.15
GF Value ₨418.18
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Ferozsons Laboratories EBIT?

Ferozsons Laboratories KAR:FEROZ -0.17% 76 EBIT is ₨2,426 Mil as of Mar. 2026. GuruFocus rates KAR:FEROZ with a GF Score™ of 76/100 and a GF Value™ of ₨418.18 (Fairly Valued). The stock has 5 warning signs investors should review.

Ferozsons Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₨519 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₨2,426 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ferozsons Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 5.74%. Ferozsons Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ferozsons Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.37%.


Ferozsons Laboratories  (KAR:FEROZ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ferozsons Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1887.248 * ( 1 - 40.57% )/( (18544.155 + 20526.388)/ 2 )
=1121.5914864/19535.2715
=5.74 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26756.019 - 5522.135 - ( 2689.729 - max(0, 8552.645 - 15105.16+2689.729))
=18544.155

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26462.806 - 4264.627 - ( 1671.791 - max(0, 8106.582 - 14541.574+1671.791))
=20526.388

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Ferozsons Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2077.864/( ( (11397.662 + max(5871.069, 0)) + (11691.058 + max(7635.579, 0)) )/ 2 )
=2077.864/( ( 17268.731 + 19326.637 )/ 2 )
=2077.864/18297.684
=11.36 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2992.362 + 8005.337 + 822.759) - (5522.135 + 0 + 427.254)
=5871.069

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3231.202 + 8357.078 + 628.094) - (4264.627 + 0 + 316.168)
=7635.579

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ferozsons Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2426.422/23397.394
=10.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ferozsons Laboratories EBIT Related Terms


Ferozsons Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Ferozsons Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ferozsons Laboratories EBIT Chart

Ferozsons Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,597.41 1,320.21 710.19 1,788.61 2,106.16

Ferozsons Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 510.49 542.47 643.20 721.29 519.47

KAR:FEROZ vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ferozsons Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ferozsons Laboratories's EV-to-EBIT falls into.


KAR:FEROZ
76GF Score
Ferozsons Laboratories Ltd KAR:FEROZ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ferozsons Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨2,426 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₨2,426 Mil mean?
Ferozsons Laboratories (KAR:FEROZ) has a EBIT of ₨2,426 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ferozsons Laboratories.
Is Ferozsons Laboratories' EBIT too high?
Ferozsons Laboratories' current EBIT is ₨2,426 Mil. Overall, Ferozsons Laboratories has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' EBIT compare to ZTS and UTHR?
Ferozsons Laboratories' EBIT of ₨2,426 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ferozsons Laboratories. Ferozsons Laboratories's current EBIT is ₨2,426 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨418.18, compared to a current price of ₨411.15 — trading 1.7% below its estimated fair value. The current EBIT is ₨2,426 Mil. Ferozsons Laboratories' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current EBIT is ₨2,426 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?

Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued. The current stock price of ₨411.15 is trading 1.7% below its estimated GF Value™ of ₨418.18. GuruFocus considers Ferozsons Laboratories to be Fairly Valued.

Key valuation signals for KAR:FEROZ:

  • EBIT: ₨2,426 Mil
  • GF Value™: ₨418.18 vs. price of ₨411.15 (1.7% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ferozsons Laboratories Business Description

Address 5 K.M Sunder Raiwind Road, Lahore, PB, PAK
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
76GF Score

Get the complete analysis for KAR:FEROZ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨411.15
Price
₨418.18
GF Value